Clinical Trials and Research

AbstractBackgroundThe Mayo transthyretin amyloid cardiomyopathy (ATTR-CM) and AMY scores were developed to identify patients at risk for ATTR-CM. However, both were…

AbstractSystemic light chain (AL) amyloidosis is a rare, acquired protein misfolding disorder characterized by extracellular deposition of misfolded immunoglobulin…

AbstractBackgroundTransthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive, often fatal disease caused by transthyretin (TTR) tetramer destabilization,…

Study OverviewBrief SummaryCardiac amyloidosis (CA) is an infiltrative disease characterized by deposits of amyloid proteins of genetic or acquired origin (often in…

This podcast by Dr. Ron Witteles reviews new data on transthyretin amyloid cardiomyopathy (ATTR‑CM), highlighting differences in transthyretin stabilization between…

Key Points Daratumumab monotherapy in stage IIIB AL amyloidosis showed rapid hematologic responses (75%; median time 1 week) and 65% 6-month survival.Treatment…

ABSTRACTIntroductionLight chain (AL) amyloidosis and transthyretin amyloid cardiomyopathy (ATTR-CM) are the most common types of cardiac amyloidosis. Despite…

ABSTRACTBACKGROUND Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive, life-threatening disease. Sociodemographic factors may influence time to…

Objective: To evaluate demographics, clinical presentation, diagnostic delay, treatment patterns, genotype-phenotype correlations, and outcomes in patients with…

AbstractBackgroundTransthyretin cardiac amyloidosis (ATTR-CM) is increasingly recognized in elderly patients with conduction disturbances and left ventricular…